OBJECTIVE: To identify genetic causes of COACH syndrome BACKGROUND: COACH syndrome is a rare autosomal recessive disorder characterised by Cerebellar vermis hypoplasia, Oligophrenia (developmental delay/mental retardation), Ataxia, Coloboma, and Hepatic fibrosis. The vermis hypoplasia falls in a spectrum of mid-hindbrain malformation called the molar tooth sign (MTS), making COACH a Joubert syndrome related disorder (JSRD). METHODS: In a cohort of 251 families with JSRD, 26 subjects in 23 families met criteria for COACH syndrome, defined as JSRD plus clinically apparent liver disease. Diagnostic criteria for JSRD were clinical findings (intellectual impairment, hypotonia, ataxia) plus supportive brain imaging findings (MTS or cerebellar vermis hypoplasia). MKS3/TMEM67 was sequenced in all subjects for whom DNA was available. In COACH subjects without MKS3 mutations, CC2D2A, RPGRIP1L and CEP290 were also sequenced. RESULTS: 19/23 families (83%) with COACH syndrome carried MKS3 mutations, compared to 2/209 (1%) with JSRD but no liver disease. Two other families with COACH carried CC2D2A mutations, one family carried RPGRIP1L mutations, and one lacked mutations in MKS3, CC2D2A, RPGRIP1L and CEP290. Liver biopsies from three subjects, each with mutations in one of the three genes, revealed changes within the congenital hepatic fibrosis/ductal plate malformation spectrum. In JSRD with and without liver disease, MKS3 mutations account for 21/232 families (9%). CONCLUSIONS: Mutations in MKS3 are responsible for the majority of COACH syndrome, with minor contributions from CC2D2A and RPGRIP1L; therefore, MKS3 should be the first gene tested in patients with JSRD plus liver disease and/or coloboma, followed by CC2D2A and RPGRIP1L.
OBJECTIVE: To identify genetic causes of COACH syndrome BACKGROUND:COACH syndrome is a rare autosomal recessive disorder characterised by Cerebellar vermis hypoplasia, Oligophrenia (developmental delay/mental retardation), Ataxia, Coloboma, and Hepatic fibrosis. The vermis hypoplasia falls in a spectrum of mid-hindbrain malformation called the molar tooth sign (MTS), making COACH a Joubert syndrome related disorder (JSRD). METHODS: In a cohort of 251 families with JSRD, 26 subjects in 23 families met criteria for COACH syndrome, defined as JSRD plus clinically apparent liver disease. Diagnostic criteria for JSRD were clinical findings (intellectual impairment, hypotonia, ataxia) plus supportive brain imaging findings (MTS or cerebellar vermis hypoplasia). MKS3/TMEM67 was sequenced in all subjects for whom DNA was available. In COACH subjects without MKS3 mutations, CC2D2A, RPGRIP1L and CEP290 were also sequenced. RESULTS: 19/23 families (83%) with COACH syndrome carried MKS3 mutations, compared to 2/209 (1%) with JSRD but no liver disease. Two other families with COACH carried CC2D2A mutations, one family carried RPGRIP1L mutations, and one lacked mutations in MKS3, CC2D2A, RPGRIP1L and CEP290. Liver biopsies from three subjects, each with mutations in one of the three genes, revealed changes within the congenital hepatic fibrosis/ductal plate malformation spectrum. In JSRD with and without liver disease, MKS3 mutations account for 21/232 families (9%). CONCLUSIONS: Mutations in MKS3 are responsible for the majority of COACH syndrome, with minor contributions from CC2D2A and RPGRIP1L; therefore, MKS3 should be the first gene tested in patients with JSRD plus liver disease and/or coloboma, followed by CC2D2A and RPGRIP1L.
Authors: F Hildebrandt; E Otto; C Rensing; H G Nothwang; M Vollmer; J Adolphs; H Hanusch; M Brandis Journal: Nat Genet Date: 1997-10 Impact factor: 38.330
Authors: Claudia Dafinger; Max Christoph Liebau; Solaf Mohamed Elsayed; Yorck Hellenbroich; Eugen Boltshauser; Georg Christoph Korenke; Francesca Fabretti; Andreas Robert Janecke; Inga Ebermann; Gudrun Nürnberg; Peter Nürnberg; Hanswalter Zentgraf; Friederike Koerber; Klaus Addicks; Ezzat Elsobky; Thomas Benzing; Bernhard Schermer; Hanno Jörn Bolz Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Jiwon M Lee; Yo Han Ahn; Hee Gyung Kang; I I Soo Ha; Kyoungbun Lee; Kyung Chul Moon; Joo Hoon Lee; Young Seo Park; Yong Mee Cho; Jun-Seok Bae; Nayoung K D Kim; Woong-Yang Park; Hae I I Cheong Journal: Pediatr Nephrol Date: 2015-03-01 Impact factor: 3.714
Authors: Katharina Hopp; Christina M Heyer; Cynthia J Hommerding; Susan A Henke; Jamie L Sundsbak; Shail Patel; Priyanka Patel; Mark B Consugar; Peter G Czarnecki; Troy J Gliem; Vicente E Torres; Sandro Rossetti; Peter C Harris Journal: Hum Mol Genet Date: 2011-04-14 Impact factor: 6.150
Authors: Changwei Li; Jiang He; Jing Chen; Jinying Zhao; Dongfeng Gu; James E Hixson; Dabeeru C Rao; Cashell E Jaquish; Treva K Rice; Yun Ju Sung; Tanika N Kelly Journal: Circ Cardiovasc Genet Date: 2017-12
Authors: Lorena Travaglini; Francesco Brancati; Jennifer Silhavy; Miriam Iannicelli; Elizabeth Nickerson; Nadia Elkhartoufi; Eric Scott; Emily Spencer; Stacey Gabriel; Sophie Thomas; Bruria Ben-Zeev; Enrico Bertini; Eugen Boltshauser; Malika Chaouch; Maria Roberta Cilio; Mirjam M de Jong; Hulya Kayserili; Gonul Ogur; Andrea Poretti; Sabrina Signorini; Graziella Uziel; Maha S Zaki; Colin Johnson; Tania Attié-Bitach; Joseph G Gleeson; Enza Maria Valente Journal: Eur J Hum Genet Date: 2013-02-06 Impact factor: 4.246
Authors: George Stratigopoulos; Jayne F Martin Carli; Diana R O'Day; Liheng Wang; Charles A Leduc; Patricia Lanzano; Wendy K Chung; Michael Rosenbaum; Dieter Egli; Daniel A Doherty; Rudolph L Leibel Journal: Cell Metab Date: 2014-05-06 Impact factor: 27.287